11046 related articles for article (PubMed ID: 22437870)
1. The blockade of immune checkpoints in cancer immunotherapy.
Pardoll DM
Nat Rev Cancer; 2012 Mar; 12(4):252-64. PubMed ID: 22437870
[TBL] [Abstract][Full Text] [Related]
2. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint blockade opens a new way to cancer immunotherapy.
Sadreddini S; Baradaran B; Aghebati-Maleki A; Sadreddini S; Shanehbandi D; Fotouhi A; Aghebati-Maleki L
J Cell Physiol; 2019 Jun; 234(6):8541-8549. PubMed ID: 30511409
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint therapy for non-small-cell lung cancer: an update.
Xia B; Herbst RS
Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
[TBL] [Abstract][Full Text] [Related]
5. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint combinations from mouse to man.
Ai M; Curran MA
Cancer Immunol Immunother; 2015 Jul; 64(7):885-92. PubMed ID: 25555570
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint blockade: a common denominator approach to cancer therapy.
Topalian SL; Drake CG; Pardoll DM
Cancer Cell; 2015 Apr; 27(4):450-61. PubMed ID: 25858804
[TBL] [Abstract][Full Text] [Related]
8. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutics for breast cancer.
Criscitiello C; Curigliano G
Curr Opin Oncol; 2013 Nov; 25(6):602-8. PubMed ID: 24076578
[TBL] [Abstract][Full Text] [Related]
10. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory receptors as targets for cancer immunotherapy.
Turnis ME; Andrews LP; Vignali DA
Eur J Immunol; 2015 Jul; 45(7):1892-905. PubMed ID: 26018646
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.
Emens LA
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1597-611. PubMed ID: 23253225
[TBL] [Abstract][Full Text] [Related]
13. [The biology of PD1 and CTLA-4 as immunotherapeutic targets and the issue of biomarkers].
Dieu-Nosjean MC; Caux C
Med Sci (Paris); 2019 Dec; 35(12):957-965. PubMed ID: 31903900
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
van der Vlist M; Kuball J; Radstake TR; Meyaard L
Nat Rev Rheumatol; 2016 Oct; 12(10):593-604. PubMed ID: 27539666
[TBL] [Abstract][Full Text] [Related]
15. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint blockade in cancer immunotherapy.
Korman AJ; Peggs KS; Allison JP
Adv Immunol; 2006; 90():297-339. PubMed ID: 16730267
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic viruses as engineering platforms for combination immunotherapy.
Twumasi-Boateng K; Pettigrew JL; Kwok YYE; Bell JC; Nelson BH
Nat Rev Cancer; 2018 Jul; 18(7):419-432. PubMed ID: 29695749
[TBL] [Abstract][Full Text] [Related]
18. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Peggs KS; Quezada SA; Allison JP
Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
[TBL] [Abstract][Full Text] [Related]
19. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
Finn OJ
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
[TBL] [Abstract][Full Text] [Related]
20. Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Borcherding N; Kolb R; Gullicksrud J; Vikas P; Zhu Y; Zhang W
J Mol Biol; 2018 Jul; 430(14):2014-2029. PubMed ID: 29800567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
